Key Takeaways
- Medication-assisted treatment with buprenorphine or methadone significantly reduces overdose risk, illicit opioid use, and relapse rates.
- Buprenorphine can be prescribed by waivered providers in office-based settings, increasingly available throughout Kentucky.
- Methadone is available through licensed opioid treatment programs (OTPs) in major Kentucky cities, requiring daily clinic visits.
- Kentucky Medicaid covers both buprenorphine and methadone with reasonable prior authorization.
- Combining MAT with behavioral therapy and counseling produces significantly better outcomes than medication alone.
- Long-term MAT maintenance is appropriate for many individuals; there is no required timeline for discontinuing medication.
Understanding Medication-Assisted Treatment
Medication-assisted treatment (MAT) represents the gold standard for treating opioid use disorders and significantly improves outcomes compared to behavioral therapy alone. MAT combines medication that binds to opioid receptors with behavioral therapy, counseling, and psychosocial support.
Two primary medications are used in MAT: buprenorphine and methadone. Both reduce cravings and prevent withdrawal; both have important differences in potency, safety, accessibility, and use patterns.
Medication combined with behavioral support is essential. Medication alone is not adequate; therapy, counseling, and social support are required. Combined treatment dramatically improves treatment retention and reduces relapse risk.
MAT is highly effective and appropriate for long-term use. If interested in MAT for opioid addiction, call Trust SoCal at (949) 280-8360 to discuss options and access Kentucky MAT programs.
Buprenorphine: Office-Based MAT
Buprenorphine is a partial opioid agonist with advantages including lower overdose risk, less severe dependence, and easier tapering if discontinuation is desired. It can be prescribed in office-based settings by waivered providers.
Buprenorphine is available as sublingual tablets or films, longer-acting injections, and combination formulations. Dosing typically ranges from 4mg to 24mg daily. Buprenorphine accessibility through office-based providers has expanded significantly, making access easier than methadone.
Kentucky Medicaid covers buprenorphine with minimal authorization. Buprenorphine is excellent for individuals new to MAT, those seeking privacy, and those in early recovery. Continued use is appropriate for many individuals.
Accessing Buprenorphine in Kentucky
Buprenorphine access has expanded throughout Kentucky. Waivered providers are located in urban and rural areas.
- Use SAMHSA Buprenorphine Waiver Locator to find waivered providers
- Ask your primary care doctor if they have a buprenorphine waiver
- Many Kentucky Medicaid-contracted providers offer buprenorphine treatment
- Most private insurance plans cover buprenorphine with minimal prior authorization
Methadone: Opioid Treatment Programs (OTPs)
Methadone is a long-acting synthetic opioid preventing withdrawal for 24+ hours, dispensed daily from licensed OTPs. Methadone remains highly effective for severe opioid use disorder.
Methadone requires daily clinic visits initially. As compliance and clean drug screens are demonstrated, individuals earn take-home privileges. Methadone is the appropriate choice for severe, chronic opioid dependence or buprenorphine failures.
Methadone maintenance is a long-term treatment, typically lasting years or indefinitely. Medically supervised tapering is available for individuals desiring discontinuation, but long-term maintenance benefits many individuals.
Combining MAT with Behavioral Support
Medication alone is not adequate treatment. Research clearly shows that medication combined with behavioral therapy, counseling, and psychosocial support produces significantly better outcomes. Behavioral components address psychological aspects of addiction, provide coping skills, and support life rebuilding around recovery.
Individual therapy addressing triggers and relapse prevention is important. Group therapy and peer support provide community connection. For many individuals, therapy continues indefinitely, evolving as needs change.
MAT is most effective when combined with regular therapy and support. Engage in counseling and community support for best outcomes.
Long-Term MAT Maintenance
Many individuals benefit from long-term or indefinite MAT maintenance. There is no universal timeline for discontinuation; duration is individualized based on recovery trajectory and needs.
For some, 6-12 months of medication is sufficient before tapering. For others, years or lifetime use is appropriate and supports sustained recovery. Medical research supports indefinite MAT for individuals benefiting from it.
Medically supervised tapering is available for individuals deciding to discontinue. Abrupt discontinuation causes withdrawal and is not recommended; instead, gradual dose reduction under medical supervision allows body adjustment.
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review
